hengrui glp 1 China's Hengrui/Kailera duo just filed an NDA for HRS9531: a dual GLP‑1/GIP agonist designed for long-term obesity treatment (not just diabetes). This strategy sets it apart from other GLP‑1 drugs. What makes Hengrui has submitted an IND
Description
Learn how GLP-1 therapy affects mens weight loss, testosterone levels, muscle mass, and fat loss
Helps regulate appetite and feelings of fullness
If you're not on a GLP-1, there are better-targeted options for general nutritional support
Does that mean the drugs caused these symptoms
Human data (from a meta-analysis of 894 participants) show fenugreek supplementation (0.5 g to 10 g daily over 4 weeks to 6 months) reduces fasting glucose, post-meal glucose, and HbA1c
This means that its natural effect in the joint is likely to be limited
